Literature DB >> 24309655

Another HIV vaccine failure: where to next?

Andrew McMichael, Louis J Picker, John P Moore, Dennis R Burton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24309655     DOI： 10.1038/nm.3413

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  15 in total

Review 1.  Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine.

Authors:  Glenda Gray; Susan Buchbinder; Ann Duerr
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

2.  Were the interests of the vulnerable truly served? The predictable failure of HIVIG.

Authors:  Arthur J Ammann; Kerry Gough; Arthur Caplan
Journal:  J Acquir Immune Defic Syndr       Date:  2012-09-01       Impact factor: 3.731

3.  Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

Authors:  Scott M Hammer; Magdalena E Sobieszczyk; Holly Janes; Shelly T Karuna; Mark J Mulligan; Doug Grove; Beryl A Koblin; Susan P Buchbinder; Michael C Keefer; Georgia D Tomaras; Nicole Frahm; John Hural; Chuka Anude; Barney S Graham; Mary E Enama; Elizabeth Adams; Edwin DeJesus; Richard M Novak; Ian Frank; Carter Bentley; Shelly Ramirez; Rong Fu; Richard A Koup; John R Mascola; Gary J Nabel; David C Montefiori; James Kublin; M Juliana McElrath; Lawrence Corey; Peter B Gilbert
Journal:  N Engl J Med       Date:  2013-10-07       Impact factor: 91.245

4.  Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans.

Authors:  David I Watkins; Dennis R Burton; Esper G Kallas; John P Moore; Wayne C Koff
Journal:  Nat Med       Date:  2008-06       Impact factor: 53.440

5.  Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo.

Authors:  Brian Moldt; Eva G Rakasz; Niccole Schultz; Po-Ying Chan-Hui; Kristine Swiderek; Kimberly L Weisgrau; Shari M Piaskowski; Zachary Bergman; David I Watkins; Pascal Poignard; Dennis R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-25       Impact factor: 11.205

6.  Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock.

Authors:  Michael Lopker; Juliet Easlick; Sarah Sterrett; Julie M Decker; Hannah Barbian; Gerald Learn; Brandon F Keele; James E Robinson; Hui Li; Beatrice H Hahn; George M Shaw; Katharine J Bar
Journal:  J Virol       Date:  2013-03-06       Impact factor: 5.103

7.  Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study).

Authors:  Ann Duerr; Yunda Huang; Susan Buchbinder; Robert W Coombs; Jorge Sanchez; Carlos del Rio; Martin Casapia; Steven Santiago; Peter Gilbert; Lawrence Corey; Michael N Robertson
Journal:  J Infect Dis       Date:  2012-05-04       Impact factor: 5.226

8.  CD8+ T-cell responses to different HIV proteins have discordant associations with viral load.

Authors:  Photini Kiepiela; Kholiswa Ngumbela; Christina Thobakgale; Dhanwanthie Ramduth; Isobella Honeyborne; Eshia Moodley; Shabashini Reddy; Chantal de Pierres; Zenele Mncube; Nompumelelo Mkhwanazi; Karen Bishop; Mary van der Stok; Kriebashnie Nair; Nasreen Khan; Hayley Crawford; Rebecca Payne; Alasdair Leslie; Julia Prado; Andrew Prendergast; John Frater; Noel McCarthy; Christian Brander; Gerald H Learn; David Nickle; Christine Rousseau; Hoosen Coovadia; James I Mullins; David Heckerman; Bruce D Walker; Philip Goulder
Journal:  Nat Med       Date:  2006-12-17       Impact factor: 53.440

9.  Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys.

Authors:  Dan H Barouch; Jinyan Liu; Hualin Li; Lori F Maxfield; Peter Abbink; Diana M Lynch; M Justin Iampietro; Adam SanMiguel; Michael S Seaman; Guido Ferrari; Donald N Forthal; Ilnour Ourmanov; Vanessa M Hirsch; Angela Carville; Keith G Mansfield; Donald Stablein; Maria G Pau; Hanneke Schuitemaker; Jerald C Sadoff; Erik A Billings; Mangala Rao; Merlin L Robb; Jerome H Kim; Mary A Marovich; Jaap Goudsmit; Nelson L Michael
Journal:  Nature       Date:  2012-01-04       Impact factor: 49.962

10.  Immune clearance of highly pathogenic SIV infection.

Authors:  Scott G Hansen; Michael Piatak; Abigail B Ventura; Colette M Hughes; Roxanne M Gilbride; Julia C Ford; Kelli Oswald; Rebecca Shoemaker; Yuan Li; Matthew S Lewis; Awbrey N Gilliam; Guangwu Xu; Nathan Whizin; Benjamin J Burwitz; Shannon L Planer; John M Turner; Alfred W Legasse; Michael K Axthelm; Jay A Nelson; Klaus Früh; Jonah B Sacha; Jacob D Estes; Brandon F Keele; Paul T Edlefsen; Jeffrey D Lifson; Louis J Picker
Journal:  Nature       Date:  2013-09-11       Impact factor: 49.962
View more
  10 in total

Review 1.  Regulation of the Cell Biology of Antigen Cross-Presentation.

Authors:  J Magarian Blander
Journal:  Annu Rev Immunol       Date:  2018-02-28       Impact factor: 28.527

Review 2.  Mucosal vaccines against respiratory syncytial virus.

Authors:  Kejian Yang; Steven M Varga
Journal:  Curr Opin Virol       Date:  2014-04-29       Impact factor: 7.090

3.  Effect of vaginal immunization with HIVgp140 and HSP70 on HIV-1 replication and innate and T cell adaptive immunity in women.

Authors:  David J M Lewis; Yufei Wang; Zhiming Huo; Raphaela Giemza; Kaboutar Babaahmady; Durdana Rahman; Robin J Shattock; Mahavir Singh; Thomas Lehner
Journal:  J Virol       Date:  2014-07-09       Impact factor: 5.103

Review 4.  Genetic Consequences of Antiviral Therapy on HIV-1.

Authors:  Miguel Arenas
Journal:  Comput Math Methods Med       Date:  2015-06-10       Impact factor: 2.238

Review 5.  RNA Viruses and RNAi: Quasispecies Implications for Viral Escape.

Authors:  John B Presloid; Isabel S Novella
Journal:  Viruses       Date:  2015-06-19       Impact factor: 5.048

Review 6.  HIV-1 vaccine immunogen design strategies.

Authors:  Jaclyn K Mann; Thumbi Ndung'u
Journal:  Virol J       Date:  2015-01-24       Impact factor: 4.099

7.  Designer antigens for elicitation of broadly neutralizing antibodies against HIV.

Authors:  Tuckweng Kok; Adriana Gaeguta; John Finnie; Paul R Gorry; Melissa Churchill; Peng Li
Journal:  Clin Transl Immunology       Date:  2014-09-26

8.  Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012).

Authors:  Michelle C Crank; Eleanor M P Wilson; Laura Novik; Mary E Enama; Cynthia S Hendel; Wenjuan Gu; Martha C Nason; Robert T Bailer; Gary J Nabel; Adrian B McDermott; John R Mascola; Richard A Koup; Julie E Ledgerwood; Barney S Graham
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

Review 9.  Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies.

Authors:  Sebastian P Fuchs; Ronald C Desrosiers
Journal:  Mol Ther Methods Clin Dev       Date:  2016-11-16       Impact factor: 6.698

Review 10.  Host Molecular Factors and Viral Genotypes in the Mother-to-Child HIV-1 Transmission in Sub-Saharan Africa.

Authors:  Linda Chapdeleine M Mouafo; Béatrice Dambaya; Nicole N Ngoufack; Céline N Nkenfou
Journal:  J Public Health Afr       Date:  2017-07-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.